Aprepitant Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 25 pharmaceutical companies such as MERCK AND CO INC, SANDOZ, MSD MERCK CO and others. It is marketed under 6 brand names, including EMEND, APREPITANT, FOSAPREPITANT DIMEGLUMINE and others. Available in 9 different strengths, such as EQ 150MG BASE/VIAL, 80MG, 125MG and others, and administered through 5 routes including POWDER;INTRAVENOUS, CAPSULE;ORAL, FOR SUSPENSION;ORAL and others.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 25 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"46778","ingredient":"APREPITANT","trade_name":"EMEND","family_id":"986abaace985429da697","publication_number":"US8258132B2","cleaned_patent_number":"8258132","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-09-26","publication_date":"2012-09-04","legal_status":"Granted"} US8258132B2 Formulation 04 Sep, 2012 Granted 26 Sep, 2027
{"application_id":"55748","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"c699976f3626438184d3","publication_number":"US10624850B2","cleaned_patent_number":"10624850","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2020-04-21","legal_status":"Granted"} US10624850B2 21 Apr, 2020 Granted 18 Sep, 2035
{"application_id":"55744","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"14757d72ed64488b9187","publication_number":"US10953018B2","cleaned_patent_number":"10953018","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2021-03-23","legal_status":"Granted"} US10953018B2 23 Mar, 2021 Granted 18 Sep, 2035
{"application_id":"55750","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"c699976f3626438184d3","publication_number":"US11173118B2","cleaned_patent_number":"11173118","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2021-11-16","legal_status":"Granted"} US11173118B2 Formulation 16 Nov, 2021 Granted 18 Sep, 2035
{"application_id":"115003","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"d880e925b6d04cf29893","publication_number":"US11744800B2","cleaned_patent_number":"11744800","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2023-09-05","legal_status":"Granted"} US11744800B2 Formulation 05 Sep, 2023 Granted 18 Sep, 2035
{"application_id":"55752","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"c699976f3626438184d3","publication_number":"US11878074B2","cleaned_patent_number":"11878074","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2024-01-23","legal_status":"Granted"} US11878074B2 23 Jan, 2024 Granted 18 Sep, 2035
{"application_id":"55742","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"14757d72ed64488b9187","publication_number":"US9974794B2","cleaned_patent_number":"9974794","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2018-05-22","legal_status":"Granted"} US9974794B2 Formulation 22 May, 2018 Granted 18 Sep, 2035
{"application_id":"55741","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"14757d72ed64488b9187","publication_number":"US9974793B2","cleaned_patent_number":"9974793","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2018-05-22","legal_status":"Granted"} US9974793B2 Formulation 22 May, 2018 Granted 18 Sep, 2035
{"application_id":"55743","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"14757d72ed64488b9187","publication_number":"US10500208B2","cleaned_patent_number":"10500208","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2019-12-10","legal_status":"Granted"} US10500208B2 Formulation 10 Dec, 2019 Granted 18 Sep, 2035
{"application_id":"138446","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"","publication_number":"US12115254B2","cleaned_patent_number":"12115254","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2024-10-15","legal_status":"Granted"} US12115254B2 Formulation 15 Oct, 2024 Granted 18 Sep, 2035
{"application_id":"138447","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"","publication_number":"US12115255B2","cleaned_patent_number":"12115255","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2024-10-15","legal_status":"Granted"} US12115255B2 Formulation 15 Oct, 2024 Granted 18 Sep, 2035
{"application_id":"242100","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"","publication_number":"US12290520B2","cleaned_patent_number":"12290520","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2025-05-06","legal_status":"Granted"} US12290520B2 Formulation 06 May, 2025 Granted 18 Sep, 2035
{"application_id":"55740","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"14757d72ed64488b9187","publication_number":"US9561229B2","cleaned_patent_number":"9561229","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2017-02-07","legal_status":"Granted"} US9561229B2 Formulation 07 Feb, 2017 Granted 18 Sep, 2035
{"application_id":"55733","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"14757d72ed64488b9187","publication_number":"US9808465B2","cleaned_patent_number":"9808465","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2017-11-07","legal_status":"Granted"} US9808465B2 07 Nov, 2017 Granted 18 Sep, 2035
{"application_id":"55749","ingredient":"APREPITANT","trade_name":"APONVIE","family_id":"c699976f3626438184d3","publication_number":"US9974742B2","cleaned_patent_number":"9974742","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2018-05-22","legal_status":"Granted"} US9974742B2 Formulation 22 May, 2018 Granted 18 Sep, 2035
{"application_id":"117523","ingredient":"FOSAPREPITANT DIMEGLUMINE","trade_name":"FOCINVEZ","family_id":"840cda4d0b174b4ab5da","publication_number":"US2022062309A1","cleaned_patent_number":"12042504","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-01-11","publication_date":"2022-03-03","legal_status":"Abandoned"} US12042504B2 Formulation 03 Mar, 2022 Abandoned 11 Jan, 2039
{"application_id":"117521","ingredient":"FOSAPREPITANT DIMEGLUMINE","trade_name":"FOCINVEZ","family_id":"840cda4d0b174b4ab5da","publication_number":"US11065265B2","cleaned_patent_number":"11065265","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-01-11","publication_date":"2021-07-20","legal_status":"Granted"} US11065265B2 Formulation 20 Jul, 2021 Granted 11 Jan, 2039

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Aprepitant

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.